Adcetris (Brentuximab vedotin)

Adcetris, or brentuximab vedotin, is a targeted cancer therapy designed to treat certain types of lymphoma, a blood cancer. It combines an antibody that recognizes specific proteins on cancer cells (CD30) with a powerful drug that kills these cells once the antibody attaches. By delivering the drug directly to cancer cells, Adcetris helps destroy tumors while minimizing damage to healthy tissues. It is usually administered through infusion and is used in cases where other treatments haven't been effective or need to be combined with other therapies.